The Mantle Cell Lymphoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Mantle Cell Lymphoma: An Overview
Mantle Cell Lymphoma (MCL) is typically an aggressive, rare, form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the “mantle zone”. The abnormal B Lymphocytes start to collect in the lymph nodes or body organs. They can then form tumors and begin to cause problems within the lymphatic system or the organ where they are growing.
About 85% of patients with Mantle Cell Lymphoma have a characteristic genetic lesion known as reciprocal translocation which is a major cause of MCL. In this genetic change, the short segment of one chromosome are moved to another chromosome. This change is considered a driver in the behavior of MCL, which likely works together with other genetic defects to cause MCL.
Mantle Cell Lymphoma Market Key Facts
As per the American Cancer Society, B-cell NHL accounts for about 85% of the total cases of NHL.
According to the Leukemia and Lymphoma Society, Mantle Cell Lymphoma patients represent only about six percent (6%) of all new cases of NHL in the United States.
According to a study titled “Epidemiology of Mantle Cell Lymphoma: A Population-Based Study in France” conducted by Leux et.al., over the period of 2002-2006, the age-standardized incidence rate of MCL (per 100,000) was 0.72 in men and 0.17 in women.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Mantle Cell Lymphoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Mantle Cell Lymphoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Mantle Cell Lymphoma Epidemiology
The epidemiology section covers insights into the historical and current Mantle Cell Lymphoma patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.
Mantle Cell Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mantle Cell Lymphoma market or expected to get launched during the study period. The analysis covers Mantle Cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Mantle Cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market
Mantle Cell Lymphoma Therapeutics Analysis
The Mantle Cell Lymphoma market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies. Companies across the globe are working towards the development of new treatment therapies for mantle cell lymphoma.
Some of the key companies in the Mantle Cell Lymphoma Market include:
Bristol-Myers Squibb (BMS)
InnoCare Pharma Tech
And many others.
Mantle Cell Lymphoma therapies covered in the report include:
TGR-1202 + Ublituximab
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Mantle Cell Lymphoma Competitive Intelligence Analysis
4. Mantle Cell Lymphoma Market Overview at a Glance
5. Mantle Cell Lymphoma Disease Background and Overview
6. Mantle Cell Lymphoma Patient Journey
7. Mantle Cell Lymphoma Epidemiology and Patient Population
8. Mantle Cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Mantle Cell Lymphoma Unmet Needs
10. Key Endpoints of Mantle Cell Lymphoma Treatment
11. Mantle Cell Lymphoma Marketed Products
12. Mantle Cell Lymphoma Emerging Therapies
13. Mantle Cell Lymphoma Seven Major Market Analysis
14. Attribute Analysis
15. Mantle Cell Lymphoma Market Outlook (7 major markets)
16. Mantle Cell Lymphoma Access and Reimbursement Overview
17. KOL Views on the Mantle Cell Lymphoma Market.
18. Mantle Cell Lymphoma Market Drivers
19. Mantle Cell Lymphoma Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
DelveInsight’s “Follicular Lymphoma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). As per DelveInsight, Follicular Lymphoma Market is expected to grow immensely in the coming years owing to the active participation of key companies such as Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States